ConSynance Therapeutics is a clinical-stage, biopharma company focused on rare central nervous system diseases.  ConSynance’s lead candidate, CSTI-500, is a Phase II ready, best-in-class Triple Monoamine Reuptake Inhibitor for Prader-Willi Syndrome, a rare genetic neurodevelopmental disorder with no adequate treatment.  To learn about Prader-Willi Syndrome, please visit www.FPWR.org.

 

Our 2nd candidate, CSTI-100, is a Phase II ready, first-in-class, Melanin-Concentrating-Hormone Receptor 1 (“MCHR1”) inhibitor for PWS as well as for Non Alcoholic Steatohepatitis (NASH).

 

Please come back to visit our new website soon!

 

In the meantime, please contact us by email info@consynance.com